High-risk infants who are breastfed are at a higher risk of HIV transmission from their mothers. Therefore, it is recommended that these infants receive a combination of antiretroviral medications to reduce the risk of transmission.

The recommended regimen for high-risk infants who are breastfed is to receive AZT (zidovudine) for 6 weeks and NVP (nevirapine) for 12 weeks. AZT is a nucleoside reverse transcriptase inhibitor that helps to reduce the viral load in the infant’s body, while NVP is a non-nucleoside reverse transcriptase inhibitor that helps to prevent the virus from replicating. By combining these two medications, the risk of HIV transmission from the mother to the infant can be significantly reduced.

It is important to follow this recommended regimen to ensure the health and well-being of the high-risk infant. Additionally, it is important to monitor the mother’s viral load to determine if NVP can be stopped if her viral load is below 1000 c/ml. This combination of medications has been shown to be effective in reducing the risk of HIV transmission from mother to child through breastfeeding.

The 2023 ART Clinical Guidelines have introduced simplified ART provision and harmonised methods of management as a new feature. This means that the guidelines aim to make it easier for healthcare providers to prescribe and manage antiretroviral therapy (ART) for patients of all ages and conditions, including children, adolescents, adults, and pregnant women living with HIV/AIDS, TB, and other common opportunistic infections. By streamlining and standardizing the approach to ART provision and management, the guidelines seek to improve the quality of care and outcomes for patients across different groups. This new feature reflects the ongoing efforts to enhance the effectiveness and accessibility of HIV treatment and care.

The first viral load (VL) measurement after ART initiation is crucial in monitoring the effectiveness of the treatment and ensuring viral suppression. By measuring the VL after 3 dispensing cycles, healthcare providers can assess how well the patient is responding to the medication and if the viral load is decreasing as expected. This early measurement allows for prompt identification of any issues with adherence or drug resistance, which can then be addressed through interventions such as adherence counseling or regimen adjustments.

Measuring the VL after 3 dispensing cycles also aligns with the goal of achieving viral suppression within the first few months of starting ART. Early detection of any challenges in achieving viral suppression can lead to timely interventions that can improve treatment outcomes and prevent the development of drug resistance. Therefore, it is important to follow the recommended guidelines and schedule the first VL measurement after 3 dispensing cycles to ensure optimal monitoring and management of HIV treatment.

The physician is seeking advice on prescribing an antidepressant for a depressed patient with HIV who is taking atazanavir. Atazanavir is an antiretroviral drug used to manage HIV, and it is important to consider potential drug interactions when prescribing other medications. In this case, the antidepressant St John’s Wort should be avoided due to its contraindication with atazanavir. St John’s Wort can reduce the efficacy of antiretroviral drugs, potentially leading to treatment failure and increased risk of HIV progression.

Among the other options provided, paroxetine, citalopram, sertraline, and amitriptyline do not have significant interactions with atazanavir and can be considered for the patient. It is important for the physician to carefully review the patient’s medical history, current medications, and potential drug interactions before prescribing an antidepressant to ensure safe and effective treatment for both depression and HIV.

This question presents a case of an 8-year-old boy with easy bruising following falls, leukocytosis, thrombocytopenia, high ESR, and a positive Paul-Bunnell test. The most probable diagnosis in this case is glandular fever, also known as infectious mononucleosis, caused by the Epstein-Barr virus (EBV).

Glandular fever is characterized by symptoms such as fatigue, fever, sore throat, and swollen lymph nodes. Leukocytosis is a common finding in infectious mononucleosis, and thrombocytopenia can also occur. The elevated ESR and positive Paul-Bunnell test further support the diagnosis of glandular fever in this case.

Idiopathic thrombocytopenic purpura (ITP) is a condition characterized by low platelet counts, but in this case, the combination of symptoms and test results point more towards glandular fever. Trauma and non-accidental injury (NAI) are less likely causes in this scenario, as the symptoms are more consistent with an underlying infectious process. Septicaemia is also less likely given the specific findings in this case.

In conclusion, the most probable diagnosis for this 8-year-old boy with easy bruising, leukocytosis, thrombocytopenia, high ESR, and a positive Paul-Bunnell test is glandular fever (infectious mononucleosis) caused by the Epstein-Barr virus.

Early latent syphilis is a stage of syphilis where the infection is present in the body but there are no visible symptoms. The recommended treatment for early latent syphilis in adults is a single dose of Benzathine penicillin G administered intramuscularly. This treatment is highly effective in curing the infection and preventing further complications. Other antibiotics such as doxycycline, amoxicillin, azithromycin, or ceftriaxone may be used as alternative treatments for patients who are allergic to penicillin. However, Benzathine penicillin G is the preferred treatment due to its high efficacy and convenience of a single dose. It is important for individuals with syphilis to seek treatment promptly to prevent the progression of the disease and reduce the risk of transmitting it to others.

Esophageal candidiasis is a fungal infection caused by Candida species, most commonly Candida albicans. Fluconazole is a preferred drug for the treatment of severe recurrent esophageal candidiasis due to its high efficacy and safety profile. It is a triazole antifungal medication that works by inhibiting the synthesis of ergosterol, a key component of the fungal cell membrane.

Nystatin is another antifungal medication that is commonly used for the treatment of oral candidiasis, but it is not as effective for esophageal candidiasis. Itraconazole is also effective for esophageal candidiasis, but fluconazole is generally preferred due to its better tolerability and ease of administration.

Amphotericin B is a polyene antifungal medication that is reserved for severe cases of esophageal candidiasis that are resistant to other antifungal drugs. Caspofungin is an echinocandin antifungal medication that is typically used for invasive fungal infections, but it may also be considered for the treatment of esophageal candidiasis in certain cases.

This question presents a case of an 11-year-old girl with a history of recurrent chest infections, fever, productive cough, anorexia, weight loss, and failure to thrive. These symptoms are highly suggestive of cystic fibrosis, a genetic disorder that affects the lungs and digestive system. Patients with cystic fibrosis often have difficulty clearing mucus from their lungs, leading to recurrent infections.

Among the options provided, Pseudomonas is the most likely organism responsible for this presentation. Pseudomonas aeruginosa is a common pathogen in patients with cystic fibrosis and is known to cause respiratory infections in these individuals. It is particularly concerning as it can form biofilms in the airways, making it difficult to treat with antibiotics.

The other options, such as Pneumococcal pneumonia, Staphylococcus, Mycobacterium TB, and PCP, are less likely in this case given the patient’s history of recurrent infections and failure to thrive, which are more indicative of cystic fibrosis. Therefore, the correct answer is Pseudomonas.

The most likely diagnosis for the 21-year-old man with general malaise, low-grade temperature, and painful ulceration of his mouth and gums is a Herpes simplex virus infection. This is indicated by the presence of gingivostomatitis, which is a characteristic feature of primary herpes simplex virus infection.

Herpetic gingivostomatitis is often the initial presentation during the first herpes simplex infection and is typically caused by HSV-1. It is more severe than herpes labialis (cold sores) and is the most common viral infection of the mouth. Symptoms of herpetic gingivostomatitis can include fever, anorexia, irritability, malaise, headache, submandibular lymphadenopathy, halitosis, and refusal to drink.

Other options such as Epstein Barr virus, Lichen planus, and HIV seroconversion illness are less likely in this case based on the presentation of symptoms. Epstein Barr virus infection may present with symptoms similar to infectious mononucleosis, Lichen planus typically presents with white, lacy patches in the mouth, and HIV seroconversion illness may present with a variety of symptoms but typically not with the characteristic ulceration seen in herpes simplex virus infection.

When managing a client on antiretroviral therapy (ART) with a viral load ≥ 1000 c/mL after two years on a dolutegravir (DTG) or protease inhibitor (PI)-containing regimen, it is important to first assess the possible reasons for the unsuppressed viral load. One of the key factors to consider is the client’s adherence to their medication regimen.

If the client’s adherence is over 80%, it is recommended to focus on improving adherence before making any changes to the ART regimen. Resistance to dolutegravir is rare, so switching to a new regimen may not necessarily address the issue of unsuppressed viral load. By identifying and addressing the root causes of non-adherence, such as side effects, pill burden, or psychosocial factors, the client may be able to achieve viral suppression while remaining on their current regimen.

Therefore, the recommended approach in this scenario would be to focus on improving adherence before considering any changes to the ART regimen. This approach prioritizes the client’s well-being and aims to achieve viral suppression in the most effective and sustainable way possible.